Affiliation:
1. Dept of Cardiovascular Surgery, Nanfang Hosp, Southern Med Univ, Guangzhou, China
Abstract
Background:
Atherosclerotic patients exhibit abnormal glucose metabolism. Pyruvic carboxylase (PC) is a key enzyme in glucose metabolism which converts pyruvate into oxaloacetate, an intermediate reactant in both gluconeogenesis and tricarboxylic acid cycle. However, the role of PC in atherosclerosis remains unclear.
Aims:
We aimed to explore a potential target in macrophage metabolism for atherosclerosis treatment.
Methods:
We generated macrophage-specific PC knockout mice (
PC
M
KO
) by crossbreeding the
PC
fl/fl
mice with
L
yz
2
-cre mice expressing Cre-recombinase in macrophages. Bone marrow transplantation was conducted to generate
PC
fl/fl
/
Apoe
-/-
and
PC
M
KO
/
Apoe
-/-
chimaera. Mice were administered with AAV-
PCSK9
DY
followed by a 12-week high-fat diet (HFD) to induce atherosclerosis.
Results:
PC was upregulated in macrophages of human and mice with atherosclerosis. Macrophage-specific PC deficiency mitigated HFD-induced atherosclerotic lesions in both
Apoe
-/-
mice and mice injected with AAV-
PCSK9
DY
. PC deletion reduced reactive oxygen species overproduction and mitochondrial damage in macrophages. Transcriptomics revealed that PC activated the HIF-1 signal pathway by initiating metabolic reprogramming in macrophages. By preventing HIF-1α from proteasome degradation, PC induced nuclear translocation of HIF-1α in atherosclerotic aortic roots. HIF-1α stabilizer, dimethyloxalylglycine, reversed the anti-inflammatory effect of PC in macrophages exposed to hypoxia, whereas the inhibition of HIF-1α impeded the transformation of pro-inflammatory macrophages to anti-inflammatory macrophages induced by PC overexpression. Dimethyloxalylglycine reversed the beneficial effects of macrophage PC deficiency on atherosclerosis.
Conclusion:
Macrophage PC aggravates atherosclerosis by regulating metabolic reprogramming, thereby promoting inflammatory responses in macrophages through HIF-1 signal pathway.
Publisher
Ovid Technologies (Wolters Kluwer Health)